Company profile
Ayurcann Holdings Corp.
OTC: AYURF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Pickering, ONReports USD
#538 of 1,422 Healthcare companies by revenue66th-percentile growth
EA Score
57CFH 57DQ —GM 69SS 30
v0.1 · 45/100 weight · provisional
↑ 3-yr revenue growth, net margin · ↓ workforce scale, market scale
Methodology →Revenue TTM
$20.6M
Rev growth YoY (TTM)
+41.8%
Net income (FY)
-$2.5M
Employees
5
as of 2026-08-27
Market cap
$58.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$22.3M31.1M CAD2025
Net income-$2.5M-3.5M CAD2025
Operating income-$2.0M-2.8M CAD2025
Total assets$6.8M9.3M CAD2025
Liabilities$8.4M11.5M CAD2025
Equity-$1.6M-2.2M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Ayurcann Holdings Corp.’s revenue?
Ayurcann Holdings Corp. booked $22.3M in FY2025 revenue, growing 20% year over year — faster than most Healthcare companies we track, at a -11.2% net margin.
Peers · Healthcare
Body and Mind Inc.——NextCure, Inc.38DDarioHealth Corp.49DItem 9 Labs Corp.——SQZ Biotechnologies Company——Alector, Inc.40DKey facts
CEOIgal Sudman
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPickering, ON
ExchangeOTC: AYURF
Employees5
IPO date2014-11-21
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.